Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
32
IMDX Quote, Financials, Valuation and Earnings
Last price:
$5.59
Seasonality move
:
13.47%
Day range:
$5.27 - $5.69
52-week range:
$1.92 - $8.51
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
32.49x
P/B ratio:
196.14x
Volume:
39.9K
Avg. volume:
84.9K
1-year change:
133.47%
Market cap:
$153.1M
Revenue:
$1.9M
EPS (TTM):
-$2.83
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IMDX
Insight Molecular Diagnostics, Inc.
|
$285K | -$0.24 | -80.82% | -75.61% | $7.00 |
|
FONR
FONAR Corp.
|
-- | -- | -- | -- | -- |
|
PRPH
ProPhase Labs, Inc.
|
$3.6M | -$0.15 | 3.99% | -50% | $13.80 |
|
VCYT
Veracyte, Inc.
|
$124.9M | $0.32 | 11.04% | 512.7% | $47.10 |
|
XGN
Exagen, Inc.
|
$16.9M | -$0.16 | 28.21% | -14.75% | $15.43 |
|
XWEL
XWELL, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IMDX
Insight Molecular Diagnostics, Inc.
|
$5.34 | $7.00 | $153.1M | -- | $0.00 | 0% | 32.49x |
|
FONR
FONAR Corp.
|
$14.65 | -- | $92.2M | 13.24x | $0.00 | 0% | 0.89x |
|
PRPH
ProPhase Labs, Inc.
|
$0.14 | $13.80 | $6.2M | -- | $0.00 | 0% | 0.93x |
|
VCYT
Veracyte, Inc.
|
$47.75 | $47.10 | $3.8B | 125.79x | $0.00 | 0% | 7.67x |
|
XGN
Exagen, Inc.
|
$7.28 | $15.43 | $165M | -- | $0.00 | 0% | 2.32x |
|
XWEL
XWELL, Inc.
|
$0.80 | -- | $4.6M | -- | $0.00 | 0% | 0.15x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IMDX
Insight Molecular Diagnostics, Inc.
|
-51.52% | -0.107 | 3.29% | 2.57x |
|
FONR
FONAR Corp.
|
18.59% | 1.654 | 49.09% | 9.64x |
|
PRPH
ProPhase Labs, Inc.
|
52.83% | -0.268 | 40.4% | 0.07x |
|
VCYT
Veracyte, Inc.
|
3.12% | 1.341 | 1.49% | 5.74x |
|
XGN
Exagen, Inc.
|
60.83% | 0.117 | 11.39% | 3.63x |
|
XWEL
XWELL, Inc.
|
278.04% | 1.263 | 65.46% | 0.57x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IMDX
Insight Molecular Diagnostics, Inc.
|
-$423K | -$7.7M | -1767.73% | -1008.03% | -2950% | -$5.6M |
|
FONR
FONAR Corp.
|
$10.4M | $3.2M | 4.68% | 5.84% | 12.26% | -$636K |
|
PRPH
ProPhase Labs, Inc.
|
-$650.5K | -$4.8M | -51.85% | -90.24% | -539.52% | -$3.5M |
|
VCYT
Veracyte, Inc.
|
$89.4M | $23.1M | 2.43% | 2.52% | 17.53% | $42M |
|
XGN
Exagen, Inc.
|
$10.1M | -$3.1M | -49.66% | -140.03% | -17.98% | $2.7M |
|
XWEL
XWELL, Inc.
|
$1.3M | -$282K | -84.75% | -224.93% | -3.84% | -$3.1M |
Insight Molecular Diagnostics, Inc. vs. Competitors
-
Which has Higher Returns IMDX or FONR?
FONAR Corp. has a net margin of -4174.62% compared to Insight Molecular Diagnostics, Inc.'s net margin of 10.25%. Insight Molecular Diagnostics, Inc.'s return on equity of -1008.03% beat FONAR Corp.'s return on equity of 5.84%.
Company Gross Margin Earnings Per Share Invested Capital IMDXInsight Molecular Diagnostics, Inc.-162.69% -$0.34 -$6.1M FONRFONAR Corp.40.11% $0.34 $201.3M -
What do Analysts Say About IMDX or FONR?
Insight Molecular Diagnostics, Inc. has a consensus price target of $7.00, signalling upside risk potential of 31.09%. On the other hand FONAR Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Insight Molecular Diagnostics, Inc. has higher upside potential than FONAR Corp., analysts believe Insight Molecular Diagnostics, Inc. is more attractive than FONAR Corp..
Company Buy Ratings Hold Ratings Sell Ratings IMDXInsight Molecular Diagnostics, Inc.1 2 0 FONRFONAR Corp.0 0 0 -
Is IMDX or FONR More Risky?
Insight Molecular Diagnostics, Inc. has a beta of 1.183, which suggesting that the stock is 18.332% more volatile than S&P 500. In comparison FONAR Corp. has a beta of 1.000, suggesting its less volatile than the S&P 500 by 0.021000000000004%.
-
Which is a Better Dividend Stock IMDX or FONR?
Insight Molecular Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. FONAR Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insight Molecular Diagnostics, Inc. pays -- of its earnings as a dividend. FONAR Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMDX or FONR?
Insight Molecular Diagnostics, Inc. quarterly revenues are $260K, which are smaller than FONAR Corp. quarterly revenues of $26M. Insight Molecular Diagnostics, Inc.'s net income of -$10.9M is lower than FONAR Corp.'s net income of $2.7M. Notably, Insight Molecular Diagnostics, Inc.'s price-to-earnings ratio is -- while FONAR Corp.'s PE ratio is 13.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insight Molecular Diagnostics, Inc. is 32.49x versus 0.89x for FONAR Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMDXInsight Molecular Diagnostics, Inc.32.49x -- $260K -$10.9M FONRFONAR Corp.0.89x 13.24x $26M $2.7M
-
Which has Higher Returns IMDX or PRPH?
ProPhase Labs, Inc. has a net margin of -4174.62% compared to Insight Molecular Diagnostics, Inc.'s net margin of -774.52%. Insight Molecular Diagnostics, Inc.'s return on equity of -1008.03% beat ProPhase Labs, Inc.'s return on equity of -90.24%.
Company Gross Margin Earnings Per Share Invested Capital IMDXInsight Molecular Diagnostics, Inc.-162.69% -$0.34 -$6.1M PRPHProPhase Labs, Inc.-73.67% -$0.16 $14.5M -
What do Analysts Say About IMDX or PRPH?
Insight Molecular Diagnostics, Inc. has a consensus price target of $7.00, signalling upside risk potential of 31.09%. On the other hand ProPhase Labs, Inc. has an analysts' consensus of $13.80 which suggests that it could grow by 10099.56%. Given that ProPhase Labs, Inc. has higher upside potential than Insight Molecular Diagnostics, Inc., analysts believe ProPhase Labs, Inc. is more attractive than Insight Molecular Diagnostics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IMDXInsight Molecular Diagnostics, Inc.1 2 0 PRPHProPhase Labs, Inc.0 0 0 -
Is IMDX or PRPH More Risky?
Insight Molecular Diagnostics, Inc. has a beta of 1.183, which suggesting that the stock is 18.332% more volatile than S&P 500. In comparison ProPhase Labs, Inc. has a beta of -0.657, suggesting its less volatile than the S&P 500 by 165.684%.
-
Which is a Better Dividend Stock IMDX or PRPH?
Insight Molecular Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insight Molecular Diagnostics, Inc. pays -- of its earnings as a dividend. ProPhase Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMDX or PRPH?
Insight Molecular Diagnostics, Inc. quarterly revenues are $260K, which are smaller than ProPhase Labs, Inc. quarterly revenues of $883K. Insight Molecular Diagnostics, Inc.'s net income of -$10.9M is lower than ProPhase Labs, Inc.'s net income of -$6.8M. Notably, Insight Molecular Diagnostics, Inc.'s price-to-earnings ratio is -- while ProPhase Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insight Molecular Diagnostics, Inc. is 32.49x versus 0.93x for ProPhase Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMDXInsight Molecular Diagnostics, Inc.32.49x -- $260K -$10.9M PRPHProPhase Labs, Inc.0.93x -- $883K -$6.8M
-
Which has Higher Returns IMDX or VCYT?
Veracyte, Inc. has a net margin of -4174.62% compared to Insight Molecular Diagnostics, Inc.'s net margin of 14.51%. Insight Molecular Diagnostics, Inc.'s return on equity of -1008.03% beat Veracyte, Inc.'s return on equity of 2.52%.
Company Gross Margin Earnings Per Share Invested Capital IMDXInsight Molecular Diagnostics, Inc.-162.69% -$0.34 -$6.1M VCYTVeracyte, Inc.67.76% $0.24 $1.3B -
What do Analysts Say About IMDX or VCYT?
Insight Molecular Diagnostics, Inc. has a consensus price target of $7.00, signalling upside risk potential of 31.09%. On the other hand Veracyte, Inc. has an analysts' consensus of $47.10 which suggests that it could fall by -1.36%. Given that Insight Molecular Diagnostics, Inc. has higher upside potential than Veracyte, Inc., analysts believe Insight Molecular Diagnostics, Inc. is more attractive than Veracyte, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IMDXInsight Molecular Diagnostics, Inc.1 2 0 VCYTVeracyte, Inc.8 2 1 -
Is IMDX or VCYT More Risky?
Insight Molecular Diagnostics, Inc. has a beta of 1.183, which suggesting that the stock is 18.332% more volatile than S&P 500. In comparison Veracyte, Inc. has a beta of 1.829, suggesting its more volatile than the S&P 500 by 82.869%.
-
Which is a Better Dividend Stock IMDX or VCYT?
Insight Molecular Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insight Molecular Diagnostics, Inc. pays -- of its earnings as a dividend. Veracyte, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMDX or VCYT?
Insight Molecular Diagnostics, Inc. quarterly revenues are $260K, which are smaller than Veracyte, Inc. quarterly revenues of $131.9M. Insight Molecular Diagnostics, Inc.'s net income of -$10.9M is lower than Veracyte, Inc.'s net income of $19.1M. Notably, Insight Molecular Diagnostics, Inc.'s price-to-earnings ratio is -- while Veracyte, Inc.'s PE ratio is 125.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insight Molecular Diagnostics, Inc. is 32.49x versus 7.67x for Veracyte, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMDXInsight Molecular Diagnostics, Inc.32.49x -- $260K -$10.9M VCYTVeracyte, Inc.7.67x 125.79x $131.9M $19.1M
-
Which has Higher Returns IMDX or XGN?
Exagen, Inc. has a net margin of -4174.62% compared to Insight Molecular Diagnostics, Inc.'s net margin of -41.1%. Insight Molecular Diagnostics, Inc.'s return on equity of -1008.03% beat Exagen, Inc.'s return on equity of -140.03%.
Company Gross Margin Earnings Per Share Invested Capital IMDXInsight Molecular Diagnostics, Inc.-162.69% -$0.34 -$6.1M XGNExagen, Inc.58.43% -$0.31 $46.3M -
What do Analysts Say About IMDX or XGN?
Insight Molecular Diagnostics, Inc. has a consensus price target of $7.00, signalling upside risk potential of 31.09%. On the other hand Exagen, Inc. has an analysts' consensus of $15.43 which suggests that it could grow by 111.93%. Given that Exagen, Inc. has higher upside potential than Insight Molecular Diagnostics, Inc., analysts believe Exagen, Inc. is more attractive than Insight Molecular Diagnostics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IMDXInsight Molecular Diagnostics, Inc.1 2 0 XGNExagen, Inc.8 0 0 -
Is IMDX or XGN More Risky?
Insight Molecular Diagnostics, Inc. has a beta of 1.183, which suggesting that the stock is 18.332% more volatile than S&P 500. In comparison Exagen, Inc. has a beta of 1.801, suggesting its more volatile than the S&P 500 by 80.089%.
-
Which is a Better Dividend Stock IMDX or XGN?
Insight Molecular Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exagen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insight Molecular Diagnostics, Inc. pays -- of its earnings as a dividend. Exagen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMDX or XGN?
Insight Molecular Diagnostics, Inc. quarterly revenues are $260K, which are smaller than Exagen, Inc. quarterly revenues of $17.2M. Insight Molecular Diagnostics, Inc.'s net income of -$10.9M is lower than Exagen, Inc.'s net income of -$7.1M. Notably, Insight Molecular Diagnostics, Inc.'s price-to-earnings ratio is -- while Exagen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insight Molecular Diagnostics, Inc. is 32.49x versus 2.32x for Exagen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMDXInsight Molecular Diagnostics, Inc.32.49x -- $260K -$10.9M XGNExagen, Inc.2.32x -- $17.2M -$7.1M
-
Which has Higher Returns IMDX or XWEL?
XWELL, Inc. has a net margin of -4174.62% compared to Insight Molecular Diagnostics, Inc.'s net margin of -2.87%. Insight Molecular Diagnostics, Inc.'s return on equity of -1008.03% beat XWELL, Inc.'s return on equity of -224.93%.
Company Gross Margin Earnings Per Share Invested Capital IMDXInsight Molecular Diagnostics, Inc.-162.69% -$0.34 -$6.1M XWELXWELL, Inc.17.32% -$0.26 $13M -
What do Analysts Say About IMDX or XWEL?
Insight Molecular Diagnostics, Inc. has a consensus price target of $7.00, signalling upside risk potential of 31.09%. On the other hand XWELL, Inc. has an analysts' consensus of -- which suggests that it could grow by 775%. Given that XWELL, Inc. has higher upside potential than Insight Molecular Diagnostics, Inc., analysts believe XWELL, Inc. is more attractive than Insight Molecular Diagnostics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IMDXInsight Molecular Diagnostics, Inc.1 2 0 XWELXWELL, Inc.0 0 0 -
Is IMDX or XWEL More Risky?
Insight Molecular Diagnostics, Inc. has a beta of 1.183, which suggesting that the stock is 18.332% more volatile than S&P 500. In comparison XWELL, Inc. has a beta of 1.227, suggesting its more volatile than the S&P 500 by 22.697%.
-
Which is a Better Dividend Stock IMDX or XWEL?
Insight Molecular Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insight Molecular Diagnostics, Inc. pays -- of its earnings as a dividend. XWELL, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMDX or XWEL?
Insight Molecular Diagnostics, Inc. quarterly revenues are $260K, which are smaller than XWELL, Inc. quarterly revenues of $7.3M. Insight Molecular Diagnostics, Inc.'s net income of -$10.9M is lower than XWELL, Inc.'s net income of -$211K. Notably, Insight Molecular Diagnostics, Inc.'s price-to-earnings ratio is -- while XWELL, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insight Molecular Diagnostics, Inc. is 32.49x versus 0.15x for XWELL, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMDXInsight Molecular Diagnostics, Inc.32.49x -- $260K -$10.9M XWELXWELL, Inc.0.15x -- $7.3M -$211K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
67
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
39
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
38
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
